AstraZeneca's Drug Fasenra Flops in COPD Trial AstraZeneca's Drug Fasenra Flops in COPD Trial

AstraZeneca's said its first respiratory biologic medicine Fasenra (benralizumab) failed to meet its target in a clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Related Links:

The five Muscarinic Acetylcholine (ACh) receptors are G-protein coupled receptors (M1R-M5R). M1R, M3R and M5R selectively couple to Gq/G11; M2R and M4R selectively couple to Gi/Go. M3 muscarinic ACh receptors are present in the central nervous system and the periphery.M3R knockout mice are viable and fertile, and have no major morphological abnormalities. They have a lean phenotype. This results from a combination of reduced caloric intake and increased energy expenditure. They eat less food than wild-type mice, possibly because a central cholinergic pathway that stimulates food intake is disrupted. They also expend more e...
Source: NIDDK Research Resources - Category: Endocrinology Source Type: research
Condition:   COPD Intervention:   Other: Dance Sponsors:   West Park Healthcare Centre;   Canadian Lung Association Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Alpha 1-Antitrypsin Deficiency;   Emphysema;   COPD Interventions:   Drug: Placebo Oral Tablet;   Drug: Alvelestat oral tablet - dose 1;   Drug: Alvelestat oral tablet - dose 2 Sponsors:   Mereo BioPharma;   Syneos Health Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(MedPage Today) -- Adult exposure also linked to increased all-cause mortality in never-smokers
Source: MedPage Today Allergy - Category: Allergy & Immunology Source Type: news
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide and results in both substantial and increasing socioeconomic burden. Guidelines on COPD encourage primary care physicians to detect the disease at an early stage. Our main aim was to evaluate the accuracy of the diagnosis of COPD at the primary health care.
Source: Respiratory Medicine - Category: Respiratory Medicine Authors: Source Type: research
ConclusionsThese results suggest that childhood secondhand smoke exposure, as well as adult secondhand smoke exposure, increase the risk of chronic obstructive pulmonary disease death in adulthood. Consistent with previous studies, the results also show that adult secondhand smoke is meaningfully associated with higher mortality from vascular disease and all causes. Overall, these findings provide further evidence for reducing secondhand smoke exposure throughout life.
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
Conclusions: Based on this NMA, DH+WM, HQ+WM, and RDN+WM were potential optimal therapies in AECOPD and their safety should be strictly monitored. PMID: 30105066 [PubMed]
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Conclusion. MZP probably improves pulmonary functions in CDSCOPD through inhibiting lung inflammation, increasing expressions of AQPs, and decreasing Muc5AC expression in lung. PMID: 30105060 [PubMed]
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
People who said they had lived with a daily smoker throughout childhood were 31 percent more likely to die of COPD than those who did not grow up in a smoking household, new research from the American Cancer Society shows.
Source: WebMD Health - Category: Consumer Health News Source Type: news
Source: Pulmonary Medicine News - Doctors Lounge - Category: Respiratory Medicine Tags: Cardiology, Pediatrics, Pulmonology, Preventive Medicine, News, Source Type: news
More News: AstraZeneca | Chronic Obstructive Pulmonary | Clinical Trials | Health | Respiratory Medicine